Table 1.
Characteristics of patients at a randomly selected visit date between 2000 and 2014, after a minimum of 1 year of antiretroviral therapy, in the development sample (VACS) and validation sample (ART-CC).
| VACS (N = 28390) |
ART-CC (N = 12109) |
|||
|---|---|---|---|---|
| Random visit date | ||||
| 2000-2004 | 6587 | (23) | 1307 | (11) |
| 2005-2009 | 7753 | (27) | 4744 | (39) |
| 2010-2014 | 14050 | (49) | 6058 | (50) |
| ART Initiation | ||||
| 1996-1998 | 7929 | (28) | 1696 | (14) |
| 1999-2002 | 6454 | (23) | 3282 | (27) |
| 2003-2007 | 6510 | (23) | 3958 | (33) |
| 2008-2014 | 7497 | (26) | 3173 | (26) |
| Years on ART | ||||
| Median (IQR) | 4.2 | (2.2-7.6) | 4.2 | (2.2-7.4) |
| Age (years) | ||||
| Median (IQR) | 52 | (46-59) | 43 | (36-49) |
| Male | 27696 | (98) | 8972 | (74) |
| Race | ||||
| White | 11576 | (41) | 6840 | (56) |
| Black | 13722 | (48) | 1403 | (12) |
| Hispanic | 2225 | (8) | 255 | (2) |
| Other/unknown | 867 | (3) | 3611 | (30) |
| CD4 cell count (cells/ul) | ||||
| Median (IQR) | 435 | (249-643) | 500 | (335-690) |
| HIV-1 RNA <= 500 copies/mL | ||||
| 21561 | (76) | 10650 | (88) | |
| Hemoglobin (g/dl) | ||||
| Median (IQR) | 14.0 | (12.8-15.1) | 14.3 | (13.0-15.3) |
| FIB-4 | ||||
| <1.45 | 15782 | (56) | 8994 | (74) |
| 1.45-3.25 | 9722 | (34) | 2459 | (20) |
| >3.25 | 2886 | (10) | 656 | (5) |
| eGFR (ml/min) | ||||
| Median (IQR) | 90 | (73-105) | 101 | (87-113) |
| Hepatitis C infection | 5523 | (19) | 1803 | (15) |
| Albumin (g/dl) | ||||
| Median (IQR) | 4.0 | (3.7-4.3) | 4.3 | (4.0-4.5) |
| White blood count (k/ml) | ||||
| Median (IQR) | 5.5 | (4.3-6.9) | 5.8 | (4.7-7.2) |
| Body mass index, kg/m2 | ||||
| Median (IQR) | 25.3 | (22.4-28.7) | 24.2 | (21.7-27.2) |
| Low-risk* | 6907 | (24) | 7303 | (60) |
*
Age <50 years, CD4 >= 200, and HIV-1 RNA <= 500